GRACE :: Lung Cancer

targeted therapy

Denise Brock

Targeted Therapies in Lung Cancer Patient Forum 2017 – Presentations and Handouts

Share

Videos from the webcast Targeted Therapies Patient Forum 2017 are available for viewing, and for those who prefer to read the material, GRACE has made all speaker presentations and handouts available.  We have also included links to helpful social media and patient groups.  

Again, huge thanks to all of the faculty who spent their Saturday in Cleveland with our community, and thanks also to those organizations who sponsored this event – Astra Zeneca, Takeda, Boehringer Ingelheim, Ignyta, Novartis, Genentech, Caris, and Guardant Health.  

We started the day out with a warm welcome from our Forum Chair – Dr. Nathan Pennell.  For the full agenda, faculty list, presentations, and videos from the webcast, please visit the ‘webcast details’ page, available via this link.  For those who would like to view the presentations from the Targeted Therapies Patient Forum in Cleveland, please view and download all presentations and handouts here, or continue on for a list of what is available.   

The morning sessions kicked off with a warm welcome from Dr. Pennell.  

General Session
 
The Many Faces of Progression
Dr. Nathan Pennell, Cleveland Clinic Cancer Center  
Pennell – The Many Faces of Progression
 
The Role of Local Therapy
Dr. Shirish Gadgeel, Michigan Medicine, University of Michigan  
Gadgeel – Local Therapy  
 
Biopsies & Re-biopsies
Dr. Karen Reckamp, City of Hope Comprehensive Cancer Center 
Reckamp – Biopsy and Re-biopsy
 
The Question of Clinical Trials
Dr. Alice Shaw, Massachusetts General Hospital
Shaw – Question of Clinical Trials
 
The Crossroads:
Local Therapy, Chemo, Targeted  Therapy, or Immunotherapy?
Panel Discussion with Drs. Pennell,  Gadgeel, Reckamp, and Shaw, and patients John Cherol (EGFR), Matt  Hiznay (ALK), and Sara Whitlock (RET), Moderator: Dr. H. (Jack) West
 
After lunch the breakout discussions continued: 
 
ALK/ROS1
Dr. Alice Shaw, Dr. Shirish Gadgeel, and Matt Hiznay, ALK patient
Shaw ALK/ROS1 Breakout  
Gadgeel – ALK Breakout
Hiznay ALK Breakout 
ROS1ders Information
 
ALK-positive NSCLC: ALK Positive
“ALK Positive” on Facebook (closed group): https://www.facebook.com/groups/ALKPositive/ 
“ALK Positive Outreach” on Facebook (public group): https://www.facebook.com/groups/ALKPositiveOR/
 
ROS1-positive cancer (any cancer):  The ROS1ders
“ROS1 Positive (ROS1+) Cancer” on Facebook (private group):  https://www.facebook.com/groups/ROS1cancer/
“ROS1 Cancer Research Forum” on Facebook (public community): https://www.facebook.com/ROS1CancerResearchForum/
“The ROS1ders” website: http://ros1cancer.com
ROS1ders Information
 
EGFR
Dr. Nathan Pennell, Dr. H. (Jack) West, and John Cherol, EGFR patient
West – EGFR Acquired Resistance  
Pennell – EGFR Initial Treatment
 
EGFR-positive NSCLC
“LUNGevity EGFR Group” on Facebook (closed group): https://www.facebook.com/groups/EGFRlung/
EGFR-positive patients who have developed resistance to at least one TKI
EGFR Resisters Lung Cancer Patient Group” on Facebook: https://www.facebook.com/groups/1992981107603006/
EGFR-positive Exon 20 insertion cancer (any cancer)
“Exon20 Group” website http://www.exon20group.org/
 
MET/RET/BRAF
Dr. Karen Reckamp, Dr. Vamsidhar  Velcheti, and Sara Whitlock, RET patient 
Reckamp – MET-RET-BRAF breakout
Velceti – MET RET Breakout
 
RET-positive NSCLC
“LUNGevity RET Group” on Facebook: https://www.facebook.com/groups/1230457690298084/
 
The day concluded with the afternoon general session: 
 
General Session
 
Managing the Cost of Cancer Care
Dr. James P. Stevenson, Cleveland Clinic Cancer Center
Stevenson -Managing the Cost of Cancer Care
 
Patient to Patient Mentoring
Kathryn Sefcek, MHA, 4th Angel Mentoring Program  
4th Angel Mentoring Program Information
4th Angel Mentoring Program
 
Caveat Emptor: Assessing Cancer Information from Sources of  Varying Quality  
Dr. H. (Jack) West, Swedish Cancer Institute & Founder of  cancerGRACE, and Janet Freeman-Daily, ROS1 patient,  #LCSM Twitter Chat co- moderator, Cure  Today contributor, blogger.
West – Caveat Emptor: Assessing Cancer Information from Sources of Varying Quality
Find Trusted Online Info About Lung Cancer 

Please feel free to offer comments and raise questions in our Discussion Forums.


GRACE would like to thank the following sponsors for their support of this program

 


Denise Brock

Targeted Therapies in Lung Cancer Patient Forum 2017 – It’s a Wrap!

Share

 

On Saturday, September 16, 2017, patients, caregivers, family members and friends joined GRACE in Cleveland at the Taussig Cancer Center for a full day of discussion on Targeted Therapies in Lung Cancer.  We are thrilled that people joined us for this amazing and informative day.  Huge thanks to all of the faculty who spent their Saturday in Cleveland with our community, and thanks also to those organizations who sponsored this event – Astra Zeneca, Takeda, Boehringer Ingelheim, Ignyta, Novartis, Genentech, Caris, and Guardant Health.  

 

We started the day out with a warm welcome from our Forum Chair – Dr. Nathan Pennell.  For the full agenda, faculty list, presentations, and videos from the webcast, please visit the ‘webcast details’ page, available via this link.     

  Brain Power

The morning sessions continued:

The Many Faces of Progression
 Dr. Nathan Pennell
 Cleveland Clinic Cancer Center
The Role of Local Therapy
 Dr. Shirish Gadgeel
 Michigan Medicine, University of Michigan
 Biopsies & Re-biopsies
 Dr. Karen Reckamp
 City of Hope Comprehensive Cancer Center 
The Question of Clinical Trials
 Dr. Alice Shaw
 Massachusetts General Hospital
 The Crossroads:
 Local Therapy, Chemo, Targeted  Therapy, or Immunotherapy?
 Panel Discussion with Drs. Pennell,  Gadgeel, Reckamp, and Shaw,
 and patients John Cherol (EGFR), Matt  Hiznay (ALK),
 and Sara Whitlock (RET).
 Moderator: Dr. H. (Jack) West 
 
 
 
Lunch was an opportunity to have further discussion with the faculty.  Cleveland Clinic Cancer Center graciously allowed us to set up lunch on the 1st floor in their beautiful new facility.

 
 
 
 
After lunch the breakout discussions continued: 
 
ALK/ROS1
 Dr. Alice Shaw, Dr. Shirish Gadgeel,
 and Matt Hiznay, ALK patient
 EGFR
 Dr. Nathan Pennell, Dr. H. (Jack) West,
 and John Cherol, EGFR patient
 MET/RET/BRAF
 Dr. Karen Reckamp, Dr. Vamsidhar  Velcheti, and Sara Whitlock, RET patient 
 
The day concluded with the afternoon general session: 
Managing the Cost of Cancer Care
 Dr. James P. Stevenson
 Cleveland Clinic Cancer Center
 Patient to Patient Mentoring
 Kathryn Sefcek, MHA
 4th Angel Mentoring Program
 Caveat Emptor: Assessing Cancer Information from Sources of  Varying Quality  
 Dr. H. (Jack) West
 Swedish Cancer Institute & Founder of  cancerGRACE
 and Janet Freeman-Daily, ROS1 patient,  #LCSM Twitter Chat co- moderator, Cure  Today contributor, blogger
 

Please click here to visit the Targeted Therapies in Lung Cancer Webcast page for viewing the videos in full!  (Please note, we will be editing the videos to cut them down – they are in raw format at this time).

 

 

Please feel free to offer comments and raise questions in our Discussion Forums.


GRACE would like to thank the following sponsors for their support of this program

 


Denise Brock

Targeted Therapies in Lung Cancer Patient Forum 2016 – Lung Cancer Champion Award

Share

Presented by the

Global Resource for Advancing Cancer Education
in collaboration with
the University of Colorado
Cancer Center
 
On August 20, 2016, in collaboration with the University of Colorado Cancer Center, GRACE presented the Targeted Therapies in Lung Cancer Patient Forum in Aurora Colorado. We are happy to share the videos from this live and webcast forum. Our seventh video is from the lunchtime sessions, GRACE founder Dr. Jack West presents the Lung Cancer Champion Award to our distinguished guest, Chris Draft.  

Download the Agenda and Speaker Bios

 


How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.

 

GRACE Video

Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC

Share

Camidge_Ceritinib_Second_Generation_ALK_Inhibitors_Acquired_Resistance_ALK-Positive_NSCLC

 

Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.

Download Transcript

How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Transcript

One of the exciting things about the ALK field is that in a relatively short space of time, we’ve gone from defining a molecular subtype of lung cancer that responds very nicely to a first generation drug, crizotinib, that we’ve actually not got more choices. More specific, more potent ALK inhibitors have been developed: ceritinib, alectinib, brigatinib to name a few. Ceritinib is already licensed — the other two drugs have got what’s called FDA breakthrough approval. That means the FDA is very keep to look at the results, and hopefully if they’re good, will license the drug fairly quickly.

What they’re showing is, one: because they tend to be slightly cleaner drugs, they have a different side effect profile from crizotinib. For example they tend to not have the swelling of the ankles and other areas of swelling which is associated with an off target effect of crizotinib called anti-MET activity. However they’re not completely free from side effects. Ceritinib for example has a lot of gastrointestinal side effects — a lot of nausea, a lot of vomiting and diarrhea, and nearly 60% of people need a dose reduction. The alectinib and brigatinib are looking relatively cleaner in terms of the side effects.

In terms of whether they work: after the crizotinib has stopped working, people have progressed in one of two ways. Either their cancer is growing in their brain because crizotinib doesn’t penetrate into the brain very well, or the cancer has evolved and changed its biology in the presence of the crizotinib.

The good news is these next generation drugs work on both of those mechanisms. Either more is getting into the brain or the drug is just more potent, and therefore we’re seeing responses in the brain, and also they work on some of the known resistance mechanisms to crizotinib. We’re seeing 50-70% of people responding in their body after initially progressing on crizotinib.

So very rapidly we now have a clearly defined next line of therapy for ALK-positive patients progressing on crizotinib.


GRACE Video

Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

Share
GRACE Cancer Video Library - Lung

GCVL_LU-FC01_Crizotinib_First_Line_Treatment_ALK_ROS1_Rearrangements

 

Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.

Download Transcript

How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Transcript

Increasingly across many molecular subtypes of lung cancer, we’ve seen that giving a targeted drug first is better than going on chemotherapy. It doesn’t mean there’s no role for chemotherapy, but you’re going to start playing your best card first.

We’ve certainly seen within randomized studies that going on crizotinib compared to first line — what’s called platinum doublet, two drug chemotherapy — going on the targeted therapy was better. There was a higher response rate; there was a longer time before the cancer progressed.

For ROS-1, because it’s a much smaller population it’s hard to do those big randomized studies, but I think most people believe that, and I think that’s why ROS-1 probably should be in the panel of things that people look for from the get go to see if there’s a tablet that can treat your cancer more than just chemotherapy from the start.


Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243